Logo image of ALGEN.PA

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

EPA:ALGEN - Euronext Paris - Matif - FR0004053510 - Common Stock - Currency: EUR

3  -0.05 (-1.64%)

Fundamental Rating

5

Taking everything into account, ALGEN scores 5 out of 10 in our fundamental rating. ALGEN was compared to 71 industry peers in the Biotechnology industry. ALGEN scores excellent on profitability, but there are some minor concerns on its financial health. ALGEN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year ALGEN was profitable.
ALGEN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
In multiple years ALGEN reported negative operating cash flow during the last 5 years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M -4M

1.2 Ratios

The Return On Assets of ALGEN (3.96%) is better than 83.10% of its industry peers.
ALGEN has a Return On Equity of 7.06%. This is amongst the best in the industry. ALGEN outperforms 81.69% of its industry peers.
ALGEN's Return On Invested Capital of 5.79% is amongst the best of the industry. ALGEN outperforms 83.10% of its industry peers.
Industry RankSector Rank
ROA 3.96%
ROE 7.06%
ROIC 5.79%
ROA(3y)2.1%
ROA(5y)-0.32%
ROE(3y)3.96%
ROE(5y)-2.21%
ROIC(3y)N/A
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

1.3 Margins

ALGEN has a Profit Margin of 5.86%. This is in the better half of the industry: ALGEN outperforms 78.87% of its industry peers.
ALGEN's Profit Margin has improved in the last couple of years.
ALGEN has a better Operating Margin (8.09%) than 78.87% of its industry peers.
In the last couple of years the Operating Margin of ALGEN has grown nicely.
ALGEN has a better Gross Margin (92.34%) than 90.14% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
Industry RankSector Rank
OM 8.09%
PM (TTM) 5.86%
GM 92.34%
OM growth 3YN/A
OM growth 5Y13.07%
PM growth 3YN/A
PM growth 5Y8.13%
GM growth 3Y-1.3%
GM growth 5Y1.19%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALGEN has been increased compared to 1 year ago.
The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
ALGEN has a better debt/assets ratio than last year.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

An Altman-Z score of 2.46 indicates that ALGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ALGEN (2.46) is better than 71.83% of its industry peers.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN's Debt to FCF ratio of 1.41 is amongst the best of the industry. ALGEN outperforms 95.77% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ALGEN is not too dependend on debt financing.
ALGEN has a better Debt to Equity ratio (0.26) than 64.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.41
Altman-Z 2.46
ROIC/WACC0.77
WACC7.53%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M

2.3 Liquidity

A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.
With a Current ratio value of 1.92, ALGEN perfoms like the industry average, outperforming 49.30% of the companies in the same industry.
ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN has a Quick ratio (1.81) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.81
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

ALGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.89%.
Measured over the past years, ALGEN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.75% on average per year.
ALGEN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.03%.
The Revenue has been growing by 13.16% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.89%
EPS 3YN/A
EPS 5Y12.75%
EPS Q2Q%-29.99%
Revenue 1Y (TTM)15.03%
Revenue growth 3Y22.09%
Revenue growth 5Y13.16%
Sales Q2Q%14.77%

3.2 Future

ALGEN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.91% yearly.
Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 12.33% on average per year.
EPS Next Y-20%
EPS Next 2Y-41.42%
EPS Next 3Y-25.99%
EPS Next 5Y-15.91%
Revenue Next Year18.41%
Revenue Next 2Y4.86%
Revenue Next 3Y8.26%
Revenue Next 5Y12.33%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 21.43, the valuation of ALGEN can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 81.69% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 24.12. ALGEN is around the same levels.
Industry RankSector Rank
PE 21.43
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 92.96% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ALGEN is valued cheaply inside the industry as 98.59% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.28
EV/EBITDA 4.95
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

The decent profitability rating of ALGEN may justify a higher PE ratio.
A cheap valuation may be justified as ALGEN's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)1.68
EPS Next 2Y-41.42%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

ALGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENOWAY SA

EPA:ALGEN (5/8/2025, 7:00:00 PM)

3

-0.05 (-1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners9.39%
Ins Owner ChangeN/A
Market Cap28.44M
Analysts86.67
Price Target6.02 (100.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.67%
PT rev (3m)-1.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)7.69%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 21.43
Fwd PE N/A
P/S 1.33
P/FCF 6.28
P/OCF 4.12
P/B 1.6
P/tB 2.34
EV/EBITDA 4.95
EPS(TTM)0.14
EY4.67%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY15.93%
OCF(TTM)0.73
OCFY24.29%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)1.68
Profitability
Industry RankSector Rank
ROA 3.96%
ROE 7.06%
ROCE 7.62%
ROIC 5.79%
ROICexc 7.37%
ROICexgc 10.74%
OM 8.09%
PM (TTM) 5.86%
GM 92.34%
FCFM 21.15%
ROA(3y)2.1%
ROA(5y)-0.32%
ROE(3y)3.96%
ROE(5y)-2.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y12.04%
ROICexc growth 3YN/A
ROICexc growth 5Y11.6%
OM growth 3YN/A
OM growth 5Y13.07%
PM growth 3YN/A
PM growth 5Y8.13%
GM growth 3Y-1.3%
GM growth 5Y1.19%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.41
Debt/EBITDA 0.77
Cap/Depr 55.06%
Cap/Sales 11.1%
Interest Coverage 250
Cash Conversion 114.18%
Profit Quality 360.76%
Current Ratio 1.92
Quick Ratio 1.81
Altman-Z 2.46
F-Score5
WACC7.53%
ROIC/WACC0.77
Cap/Depr(3y)73.44%
Cap/Depr(5y)126.53%
Cap/Sales(3y)12.12%
Cap/Sales(5y)17.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.89%
EPS 3YN/A
EPS 5Y12.75%
EPS Q2Q%-29.99%
EPS Next Y-20%
EPS Next 2Y-41.42%
EPS Next 3Y-25.99%
EPS Next 5Y-15.91%
Revenue 1Y (TTM)15.03%
Revenue growth 3Y22.09%
Revenue growth 5Y13.16%
Sales Q2Q%14.77%
Revenue Next Year18.41%
Revenue Next 2Y4.86%
Revenue Next 3Y8.26%
Revenue Next 5Y12.33%
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5Y27.95%
EBIT Next Year76.19%
EBIT Next 3Y19.68%
EBIT Next 5Y22.96%
FCF growth 1Y67.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.68%
OCF growth 3YN/A
OCF growth 5Y7.2%